Longitudinal immune kinetics of COVID-19 booster versus primary series vaccination : Insight into the annual vaccination strategy
© 2024 The Authors..
Background: Data on the durability of booster dose immunity of COVID-19 vaccines are relatively limited.
Methods: Immunogenicity was evaluated for up to 9-12 months after the third dose of vaccination in 94 healthy adults.
Results: Following the third dose, the anti-spike immunoglobulin G (IgG) antibody response against the wild-type was boosted markedly, which decreased gradually over time. However, even 9-12 months after the booster dose, both the median and geometric mean of anti-spike IgG antibody levels were higher than those measured 4 weeks after the second dose. Breakthrough infection during the Omicron-dominant period boosted neutralizing antibody titers against Omicron sublineages (BA.1 and BA.5) and the ancestral strain. T-cell immune response was efficiently induced and maintained during the study period.
Conclusions: mRNA vaccine booster dose elicited durable humoral immunity for up to 1 year after the third dose and T-cell immunity was sustained during the study period, supporting an annual COVID-19 vaccination strategy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Heliyon - 10(2024), 5 vom: 15. März, Seite e27211 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choi, Min Joo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Booster shot |
|---|
| Anmerkungen: |
Date Revised 13.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.heliyon.2024.e27211 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369586611 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369586611 | ||
| 003 | DE-627 | ||
| 005 | 20240313234903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.heliyon.2024.e27211 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM369586611 | ||
| 035 | |a (NLM)38468934 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choi, Min Joo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Longitudinal immune kinetics of COVID-19 booster versus primary series vaccination |b Insight into the annual vaccination strategy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a Background: Data on the durability of booster dose immunity of COVID-19 vaccines are relatively limited | ||
| 520 | |a Methods: Immunogenicity was evaluated for up to 9-12 months after the third dose of vaccination in 94 healthy adults | ||
| 520 | |a Results: Following the third dose, the anti-spike immunoglobulin G (IgG) antibody response against the wild-type was boosted markedly, which decreased gradually over time. However, even 9-12 months after the booster dose, both the median and geometric mean of anti-spike IgG antibody levels were higher than those measured 4 weeks after the second dose. Breakthrough infection during the Omicron-dominant period boosted neutralizing antibody titers against Omicron sublineages (BA.1 and BA.5) and the ancestral strain. T-cell immune response was efficiently induced and maintained during the study period | ||
| 520 | |a Conclusions: mRNA vaccine booster dose elicited durable humoral immunity for up to 1 year after the third dose and T-cell immunity was sustained during the study period, supporting an annual COVID-19 vaccination strategy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Booster shot | |
| 650 | 4 | |a COVID-19 vaccines | |
| 650 | 4 | |a Immunogenicity | |
| 650 | 4 | |a Longevity | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Hyun, Hakjun |e verfasserin |4 aut | |
| 700 | 1 | |a Heo, Jung Yeon |e verfasserin |4 aut | |
| 700 | 1 | |a Seo, Yu Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Noh, Ji Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Cheong, Hee Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Woo Joo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hwa Jung |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Ju-Yeon |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Young Jae |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Eun Joo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Su-Hwan |e verfasserin |4 aut | |
| 700 | 1 | |a Jeong, Hyeonji |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Byoungguk |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Joon Young |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Heliyon |d 2015 |g 10(2024), 5 vom: 15. März, Seite e27211 |w (DE-627)NLM255913095 |x 2405-8440 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g number:5 |g day:15 |g month:03 |g pages:e27211 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.heliyon.2024.e27211 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |e 5 |b 15 |c 03 |h e27211 | ||